Evidence map›Paper›PMID 29907866›Full record

ArticleMucosal immunology2018

Intestinal damage precedes mucosal immune dysfunction in SIV infection.

Tiffany Hensley-McBain, Alicia R Berard, Jennifer A Manuzak, Charlene J Miller, Alexander S Zevin, Patricia Polacino, Jillian Gile, Brian Agricola, Mark Cameron, Shiu-Lok Hu and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Mucosal immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 70 citations in OpenAlex.

  1. Trial
  2. Maintenance of intestinal CX3CR1Nature communications · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Mucosal immunity in acute HIV: a review of recent work.Current opinion in HIV and AIDS · 2025
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. International journal of molecular sciences · 2023
    Article
  12. Review
  13. Article
  14. Article
  15. Identification of CX3CR1iScience · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Tiffany Hensley-McBainDepartment of Pharmaceutics, University of Washington, Seattle, WA, USA.
Alicia R BerardNational HIV and Retrovirology Labs, Public Health Agency of Canada, Winnipeg, MB, Canada.
Jennifer A ManuzakDepartment of Pharmaceutics, University of Washington, Seattle, WA, USA.
Charlene J MillerDepartment of Pharmaceutics, University of Washington, Seattle, WA, USA.
Alexander S ZevinDepartment of Pharmaceutics, University of Washington, Seattle, WA, USA.
Patricia PolacinoWashington National Primate Research Center, Seattle, WA, USA.
Jillian GileDepartment of Pharmaceutics, University of Washington, Seattle, WA, USA.
Brian AgricolaWashington National Primate Research Center, Seattle, WA, USA.
Mark CameronDepartment of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, USA.
Shiu-Lok HuDepartment of Pharmaceutics, University of Washington, Seattle, WA, USA.
Jacob D EstesVaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA.
R Keith ReevesCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Jeremy SmedleyWashington National Primate Research Center, Seattle, WA, USA.
Brandon F KeeleAIDS and Cancer Virus Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Adam D BurgenerNational HIV and Retrovirology Labs, Public Health Agency of Canada, Winnipeg, MB, Canada.
Nichole R KlattDepartment of Pharmaceutics, University of Washington, Seattle, WA, USA. klattnr@uw.edu.
University of Washington · USOregon National Primate Research Center · USPublic Health Agency of Canada · CABeth Israel Deaconess Medical Center · USCase Western Reserve University · USLeidos (United States) · US

Funding

Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8M
National Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5M
Diseases of Public Health Importance Training GrantT32AI007509 · NIAID · UNIVERSITY OF WASHINGTON · PI LUND, JENNIFER M · 1997 to 2024
$6.3M
Impact of Cannabis on Inflammation and Viral Persistence in Treated HIV/SIVDP1DA037979 · NIDA · UNIVERSITY OF WASHINGTON · PI KLATT, NICHOLE ROSE · 2015 to 2019
$4.3M
Targeting novel pathways to enhance gastrointestinal integrity during HIV infectionR01DK112254 · NIDDK · UNIVERSITY OF WASHINGTON · PI BURGENER, ADAM, KLATT, NICHOLE ROSE · 2017 to 2021
$1.8M
Impact of Malaria Co-Infection on HIV VaccinationK01OD024876 · OD · UNIVERSITY OF WASHINGTON · PI MANUZAK, JENNIFER · 2017 to 2019
$1.0M
Mucosal Immune Dysfunction after SIV InfectionK22AI098440 · NIAID · UNIVERSITY OF WASHINGTON · PI KLATT, NICHOLE ROSE · 2013 to 2014
$270k
CIHR TMI-138658NCI NIH HHS HHSN261200800001ENIAID NIH HHS K22 AI098440NIAID NIH HHS T32 AI007509NIDA NIH HHS DP1 DA037979NIDDK NIH HHS R01 DK112254NIH HHS P51 OD010425NIH HHS P51 OD011107
6 · The paper itself

Abstract

HIV and pathogenic SIV infection are characterized by mucosal dysfunction including epithelial barrier damage, loss of Th17 cells, neutrophil infiltration, and microbial translocation with accompanying inflammation. However, it is unclear how and when these contributing factors occur relative to one another. In order to determine whether any of these features initiates the cycle of damage, we longitudinally evaluated the kinetics of mucosal and systemic T-cell activation, microbial translocation, and Th17 cell and neutrophil frequencies following intrarectal SIV infection of rhesus macaques. We additionally assessed the colon proteome to elucidate molecular pathways altered early after infection. We demonstrate increased T-cell activation (HLA-DR+) beginning 3-14 days post-SIV challenge, reduced peripheral zonulin 3-14 days post-SIV, and evidence of microbial translocation 14 days post-SIV. The onset of mucosal dysfunction preceded peripheral and mucosal Th17 depletion, which occurred 14-28 days post-SIV, and gut neutrophil accumulation was not observed. Proteins involved in epithelial structure were downregulated 3 days post-SIV followed by an upregulation of immune proteins 14 days post-SIV. These data demonstrate that immune perturbations such as Th17 loss and neutrophil infiltration occur after alterations to epithelial structural protein pathways, suggesting that epithelial damage occurs prior to widespread immune dysfunction.

Indexed as

AnimalsColonDown-RegulationInflammationIntestinal MucosaLongitudinal StudiesLymphocyte ActivationMacaca mulattaMaleNeutrophilsSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusTh17 CellsUp-Regulation

Identifiers

PMID29907866
PMCPMC6162106
OpenAlexW2808531824

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.